FermaVir Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Investor Conference; Company to Present Current Drug Development Plans for Institutional Investors and Biotech Community.NEW YORK -- FermaVir Pharmaceuticals, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: FMVR), a developer of new drug treatments for the treatment of Shingles and Cytomegalovirus infections, will present its progress and development plans at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , a high-profile forum for institutional investors and other professionals in the worldwide biotechnology industry. Dr. Geoffrey Henson, Chief Executive Officer, will highlight FermaVir's proprietary technology during a session scheduled for Tuesday, November 8, at 9:45 a.m., in the Adams Salon of the New York Palace
"We will provide an overview of our Company's drug development program, including an overview of the Shingles treatment market our drug candidate is designed to address," Dr. Henson said. "FermaVir has selected a clinical candidate, CF-1743, for development for the treatment of Shingles, a disease caused by the varicella varicella: see chicken pox. zoster zoster /zos·ter/ (zos?ter) herpes zoster. zos·ter n. See shingles. zoster, See herpes zoster. virus which affects more than a million Americans a year. Research is also ongoing to select potential lead compounds for the treatment of Cytomegalovirus infections, a major problem in transplant and other immuno-suppressed patients." The Rodman & Renshaw Techvest healthcare conferences are designed to attract institutional investors, venture capitalists, private investors, business development professionals and other investment professionals. About Rodman & Renshaw Rodman & Renshaw is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research and the development of institutional support. During the last two years, Rodman & Renshaw completed over 75 financing transactions, totaling over $1.2 billion. Rodman & Renshaw concentrates on emerging growth companies in the life science and technology sectors. More information is available at www.rodmanandrenshaw.com. About FermaVir Pharmaceuticals, Inc. FermaVir is a development stage biotechnology company that has licensed patents on a series of compounds for the treatment of viral diseases including compounds for the treatment of varicella zoster virus ("VZV VZV Varicella-zoster virus, see there "), the causative agent for shingles and chickenpox chickenpox or varicella Contagious viral disease producing itchy blisters. It usually occurs in epidemics among young children, causes a low fever, and runs a mild course, leaving patients immune. The blisters can scar if scratched. and human cytomegalovirus cytomegalovirus (sī'təmĕg'əlōvī`rəs), member of the herpesvirus family that can cause serious complications in persons with weakened immune systems. ("CMV CMV cytomegalovirus. CMV abbr. 1. controlled mechanical ventilation 2. cytomegalovirus Cytomegalovirus (CMV) "), a member of the herpes virus group which includes the viruses that cause chicken pox chicken pox or varicella (vâr'əsĕl`ə), infectious disease usually occurring in childhood. It is believed to be caused by the same herpesvirus that produces shingles. , mononucleosis mononucleosis /mono·nu·cle·o·sis/ (-noo?kle-o´sis) excess of mononuclear leukocytes (monocytes) in the blood. chronic mononucleosis chronic fatigue syndrome. , herpes labialis (cold sores) and genitalis (genital herpes). FermaVir has selected a clinical candidate for development for the treatment of shingles. In addition, FermaVir intends to identify from its proprietary anti-viral compounds, a clinical candidate for the treatment of CMV infections in transplant patients. FermaVir is also currently seeking other opportunities and technologies for in-licensing from academic, research institutions and commercial sources which would complement and enhance its business. Forward-Looking Statements Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although FermaVir believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Descriptive Memorandum filed as an exhibit to the FermaVir Pharmaceuticals Form 8-K, as filed with the Securities and Exchange Commission on August 22, 2005, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that FermaVir will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion